|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Fujita T et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006;94(2):247-52. Abstract
Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2
and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. San Antonio Breast Cancer Symposium 2005;Abstract 46.
Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res 2006;12(3 Pt 2):1019-23. Abstract
Paik S. Molecular profiling of breast cancer. Curr Opin Obstet Gynecol 2006;18(1):59-63. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3724-6. Abstract
Paik S et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. Proc ASCO 2005;Abstract 510.
Paik S et al. Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol 2005;2(5):246-54. Abstract
Paik S et al. Real-world performance of HER2 testing — National Surgical Adjuvant
Breast and Bowel Project Experience. J Natl Cancer Inst 2002;94(11):852-4. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Shak S et al. Relationship between proliferation genes and expression of hormone and growth factor receptors: Quantitative RT-PCR in 10,618 breast cancers. San Antonio Breast Cancer Symposium 2006;Abstract 6111.
Wolff AC et al. American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-45. Abstract
 |
 |
